Curaleaf launches formal hostile bid for Aurora Cannabis
The US-based firm offers US$4 per share, a 45% premium, to secure access to EU-GMP cultivation capacity and the German medical cannabis market.
Curaleaf has formally launched a hostile takeover bid for Aurora Cannabis, offering US$4 per share. The proposal, made official on Monday, represents a 45% premium over Aurora’s 30-day average share price, calculated as of 10 August prior to the initial announcement of Curaleaf’s intentions. The move follows the collapse of direct negotiations between the two companies’ executives, with Curaleaf CEO Boris Jordan stating that earlier conversations with Aurora CEO Miguel Martin had "sputtered out."
The primary strategic motivation for the bid is access to Aurora’s EU-GMP (Good Manufacturing Practice) cultivation capacity. This asset allows for medical cannabis exports to the European Union, with Germany identified as the key target market due to its population of approximately 84 million and strict standards for imported medical cannabis. US federal restrictions make it difficult for US-based firms like Curaleaf to directly export cannabis, making the acquisition of Aurora’s Canadian and EU-compliant assets strategically valuable.
Curaleaf claims the merger would yield approximately US$40 million in annual cost synergies. The combined entity is projected to have a market capitalisation of approximately US$3 billion. In a statement, Jordan indicated that the offer provides Aurora shareholders with immediate value and exposure to the US consumer cannabis market, described as the world’s largest. Curaleaf characterised the combined company as a "premier public vehicle" for institutional and long-term investors seeking exposure to legal cannabis.
The tone of the bid has been notably aggressive. Curaleaf’s press release characterised Aurora as having a "sustained track record of value destruction," citing C$4.56 billion in impairment charges recognised between 2020 and 2026. Jordan had previously indicated he wanted the overture to be "friendly," but the formal proposal includes stark language regarding Aurora’s financial performance.
Aurora’s board has established a special committee to review the proposal. Both companies’ shares surged following the initial announcement last week. At the time of reporting, Aurora was up approximately 1.5% intraday, while Curaleaf slipped about 2%.
Jordan indicated that if the bid fails, Curaleaf has "plan B and plan C" alternatives, including building its own capacity rather than buying. The outcome of the bid remains uncertain, as hostile acquisitions in the sector often face significant hurdles.
